Indexed In
- Open J Gate
- Genamics JournalSeek
- Academic Keys
- JournalTOCs
- ResearchBible
- Electronic Journals Library
- RefSeek
- Hamdard University
- EBSCO A-Z
- OCLC- WorldCat
- Proquest Summons
- SWB online catalog
- Virtual Library of Biology (vifabio)
- Publons
- MIAR
- Euro Pub
- Google Scholar
Useful Links
Share This Page
Journal Flyer
Open Access Journals
- Agri and Aquaculture
- Biochemistry
- Bioinformatics & Systems Biology
- Business & Management
- Chemistry
- Clinical Sciences
- Engineering
- Food & Nutrition
- General Science
- Genetics & Molecular Biology
- Immunology & Microbiology
- Medical Sciences
- Neuroscience & Psychology
- Nursing & Health Care
- Pharmaceutical Sciences
FAAAAI
FAAAAI
Bolivarian Rep. of Venezuela
Publications
-
Review Article
Personalized Medicine for Severe Asthma: How Far Have We Achieved?
Author(s): Ting F Leung, FAAAAI, Man F Tang and Gary WK Wong Ting F Leung, FAAAAI, Man F Tang and Gary WK Wong
There is increasing pharmacogenetic literature on the heterogeneity in the treatment responses to different anti-asthma drugs including inhaled corticosteroid (ICS), which are indicated for patients with moderate-to-severe asthma. A number of genetic targets including STIP1, CRHR1, CYP3A4, GLCCI1, T gene and FBXL7 are potential pharmacogenetic biomarkers for predicting patients’ response to ICS. Knowledge on predictive variants in these genes allows for the genotyping and selection of patients with severe asthma for personalized treatment with high-dose ICS treatment. There is an emerging trend to unravel genetic variants that predict treatment responses among patients with different asthma endotypes. Some patients with severe asthma are refractory to maintenance corticosteroids, and several biological agents targeting type 2 helper T lymphocyte pathway offer ho.. View More»
DOI: 10.4172/2153-0645.1000148